News & Updates

Use of tenofovir disoproxil fumarate (TDF) for ≥24 months increases the risk of fracture in older patients with chronic hepatitis B (CHB), reports a study.

Vibration-controlled transient elastography (VCTE)–based Agile scores, developed for diagnosis of advanced fibrosis (Agile 3+ score) and cirrhosis (Agile 4 score) in patients with metabolic dysfunction–associated steatotic liver disease (MASLD), are highly accurate in predicting liver-related events (LREs) and may be suitable alternatives to liver biopsy in routine clinical practice and phase IIb/III clinical trials for steatohepatitis, researchers from the VCTE-Prognosis Study Group have reported.

Use of either stereotactic body radiotherapy (SBRT) or yttrium-90 (Y90) is effective in the management of hepatocellular carcinoma (HCC), resulting in similar overall and progression-free survival, reports a study. However, Y90 is more expensive than SBRT.

Patients with chronic hepatitis B (CHB) who has undergone long-term treatment with tenofovir alafenamide (TAF) achieve high rates of viral suppression comparable to those of tenofovir disoproxil fumarate (TDF; or TDF switched to TAF) with favourable renal and bone safety, results of a study have shown.

Early (eTRE) and late time-restricted eating (lTRE) both result in significantly reduced intrahepatic fat and improved body composition, liver function, and metabolic health among patients with nonalcoholic fatty liver disease (NAFLD), reports a study.